Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 6301–6350 of 76348
On October 28, 2024, the Board of Directors of M.D.C. Holdings, Inc. ("MDC") approved the departure planned for December 31, 2024 of Larry A. Mizel, MDC’s Founder Executive Chairman of the Board of Directors, and David D. Mandarich, MDC’s President, Chief Executive Officer and Director.
As previously announced, John C. Barichivich III will cease serving as the Company’s principal accounting officer upon the effective date of Mr. LaBauve’s appointment as his successor.
• Sundar Subramaniam;
• Alexander Fraser, General Counsel and Secretary.
• Dwaine Alleyne, Chief Technology Officer;
Additionally, each of the following officers of the Company and its subsidiaries were terminated as of the Effective Time: • James D. Kelly III, Chief Executive Officer;
• David L. Shrier
each of the following directors of the Company resigned as a member of the Company’s board of directors and any committees thereof as of the Effective Time: • James D. Kelly III;
• Thomas J. Zaccagnino.
• Neal Simmons
• Cristina Dolan
• Sharmila Kassam
• Michael W. Hamilton, Chief Research Officer;
• Allan J. Wallander, Chief Financial Officer and Secretary;
• Gerard F. King II, Chief Operating Officer
Sanjay Goel, Executive Vice President and President, Asia-Pacific, of American Tower Corporation (the “Company”), will leave the Company effective March 31, 2025.
terminated Peter George, President and Chief Executive Officer of the Company without cause, effective immediately.
The information set forth above in Item 1.01 of this Current Report on Form 8-K regarding Mr. Folker’s resignation is incorporated into this Item 5.02 by reference.
Pursuant to the Merger Agreement, at the Effective Time, Jeff Allred, Jeff Arnold, John Chadwick, Sandro Galea, Ken Goulet, Brent Layton, Veronica Mallett, Alan Mnuchin, Rajeev Ronanki, Jeff Sagansky and Nicole Torraco each resigned from the Board and from any and all committees of the Board on which they served.
Pursuant to the Merger Agreement, at the Effective Time, Jeff Allred, Jeff Arnold, John Chadwick, Sandro Galea, Ken Goulet, Brent Layton, Veronica Mallett, Alan Mnuchin, Rajeev Ronanki, Jeff Sagansky and Nicole Torraco each resigned from the Board and from any and all committees of the Board on which they served.
Pursuant to the Merger Agreement, at the Effective Time, Jeff Allred, Jeff Arnold, John Chadwick, Sandro Galea, Ken Goulet, Brent Layton, Veronica Mallett, Alan Mnuchin, Rajeev Ronanki, Jeff Sagansky and Nicole Torraco each resigned from the Board and from any and all committees of the Board on which they served.
Pursuant to the Merger Agreement, at the Effective Time, Jeff Allred, Jeff Arnold, John Chadwick, Sandro Galea, Ken Goulet, Brent Layton, Veronica Mallett, Alan Mnuchin, Rajeev Ronanki, Jeff Sagansky and Nicole Torraco each resigned from the Board and from any and all committees of the Board on which they served.
Pursuant to the Merger Agreement, at the Effective Time, Jeff Allred, Jeff Arnold, John Chadwick, Sandro Galea, Ken Goulet, Brent Layton, Veronica Mallett, Alan Mnuchin, Rajeev Ronanki, Jeff Sagansky and Nicole Torraco each resigned from the Board and from any and all committees of the Board on which they served.
Pursuant to the Merger Agreement, at the Effective Time, Jeff Allred, Jeff Arnold, John Chadwick, Sandro Galea, Ken Goulet, Brent Layton, Veronica Mallett, Alan Mnuchin, Rajeev Ronanki, Jeff Sagansky and Nicole Torraco each resigned from the Board and from any and all committees of the Board on which they served.
Pursuant to the Merger Agreement, at the Effective Time, Jeff Allred, Jeff Arnold, John Chadwick, Sandro Galea, Ken Goulet, Brent Layton, Veronica Mallett, Alan Mnuchin, Rajeev Ronanki, Jeff Sagansky and Nicole Torraco each resigned from the Board and from any and all committees of the Board on which they served.
Pursuant to the Merger Agreement, at the Effective Time, Jeff Allred, Jeff Arnold, John Chadwick, Sandro Galea, Ken Goulet, Brent Layton, Veronica Mallett, Alan Mnuchin, Rajeev Ronanki, Jeff Sagansky and Nicole Torraco each resigned from the Board and from any and all committees of the Board on which they served.
Pursuant to the Merger Agreement, at the Effective Time, Jeff Allred, Jeff Arnold, John Chadwick, Sandro Galea, Ken Goulet, Brent Layton, Veronica Mallett, Alan Mnuchin, Rajeev Ronanki, Jeff Sagansky and Nicole Torraco each resigned from the Board and from any and all committees of the Board on which they served.
Pursuant to the Merger Agreement, at the Effective Time, Jeff Allred, Jeff Arnold, John Chadwick, Sandro Galea, Ken Goulet, Brent Layton, Veronica Mallett, Alan Mnuchin, Rajeev Ronanki, Jeff Sagansky and Nicole Torraco each resigned from the Board and from any and all committees of the Board on which they served.
Pursuant to the Merger Agreement, at the Effective Time, Jeff Allred, Jeff Arnold, John Chadwick, Sandro Galea, Ken Goulet, Brent Layton, Veronica Mallett, Alan Mnuchin, Rajeev Ronanki, Jeff Sagansky and Nicole Torraco each resigned from the Board and from any and all committees of the Board on which they served.
Effective October 29, 2024, Dr. Kristi D. Snell, Ph.D., resigned from her position as Vice President Research and Chief Science Officer of Yield10 Bioscience, Inc. (the Company").
On October 29, 2024, pursuant to the terms of the Repurchase Agreement, Mr. Cornell provided notice of his retirement from the Board (including as a member of any and all committees thereof) effective as of the date of the 2025 Annual Meeting and stated his intent to not stand for re-election to the Board (including as a member of any and all committees thereof) at the 2025 Annual Meeting.
Mr. Stark gave notice of his intent to resign on October 25, 2024 and the retirement of Mr. Stark as Chief Financial Officer of the Company was not due to any disagreement with the Company.
Michael Koenig, the Chief Operating Officer since October 31, 2022, has left the Company effective October 30, 2024.
Effective as of October 25, 2024, David Knight, the President and Chief Executive Officer of Jones Soda Co. (the “Company”) departed the Company being replaced by Paul Norman, the Chairman of the Board of Directors of the Company, who will serve as Interim President and Chief Executive Officer of the Company effective as of October 25, 2024.
Effective October 25, 2024, Naveen Bhatia voluntarily resigned from his position as a member of the board of directors (the “Board”) of LifeMD, Inc. (the “Company”).
the employment of James Ferguson, M.D., the Company’s Chief Medical Officer, was terminated effective October 31, 2024.
On October 25, 2024, Robert Oliva resigned as President of Novo Integrated Sciences, Inc. (the “Company”), effective immediately.
Nathaniel Christopher Kelly departed as Chief Revenue Officer of TILT Holdings Inc. (the “Company”) on October 14, 2024.
On October 31, 2024, the Company and Richard Tajer, President of Electrical Systems, reached a separation agreement (the “Separation Agreement”) pursuant to which Mr. Tajer will cease being President of Elecrical Systems effective immediately and cease being an employee effective December 31, 2024.
Chris Bruzzo will step down as Interim co-CEO and Interim co-President on November 1, 2024.
On the same day Tal Wilkes Glazer resigned her position as Director, CEO & Board Member. Her resignation was not the result of any dispute with the Company.
On October 29, 2024, James E. Callaway and Adam Logal, each a member of the board of directors (the “Board”) of Xenetic Biosciences, Inc. (the “Company”), informed the Company of their intention to not stand for re-election at the Company’s 2024 Annual Meeting of Stockholders.
On October 29, 2024, James E. Callaway and Adam Logal, each a member of the board of directors (the “Board”) of Xenetic Biosciences, Inc. (the “Company”), informed the Company of their intention to not stand for re-election at the Company’s 2024 Annual Meeting of Stockholders.
On October 29, 2024, Anirvan Coomer resigned from the Board effective immediately.
Daniel P. Amos, who has been serving as President of the Company since November 16, 2023, will resign as President effective January 1, 2025,
On October 28, 2024, Richard D. Moss gave notice to the Board of Directors of his intention to resign from the Board at the 2024 annual meeting of shareholders.
Shelly R. Ibach, Chair, President and Chief Executive Officer of Sleep Number Corporation (the “Company”), informed the Company’s Board of Directors that she will retire from the Company and Board no later than the 2025 Annual Meeting of Shareholders (the “2025 Annual Meeting”).
On October 24, 2024, Brian Kei, the Chief Operating Officer of the Company, resigned as an officer of the Company, effective October 25, 2024.
On October 28, 2024, Jacqueline Hernández, who had been serving as the Company’s interim Chief Executive Officer and President, ceased to serve in such capacities, having served the full six-month term of her engagement
On October 30, 2024, Stepan Company (the “Company”) announced that the Board of Directors (the “Board”) of the Company appointed Luis E. Rojo as President and Chief Executive Officer and as a member of the Board with a term expiring at the annual meeting to be held in 2025, effective immediately, succeeding Scott R. Behrens, who is departing the Company to pursue other opportunities.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.